TY  -  
T1  - Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure A Randomized Trial 
SN  -  /  
UR  - http://hdl.handle.net/10138/340512 
T3  -  
A1  - SOLOIST-WHF Comm Investigators; Szarek, Michael; Bhatt, Deepak L.; Steg, Ph Gabriel; Harjola, Veli-Pekka 
A2  -  
PB  -  
Y1  - 2021 
LA  - eng 
AB  - Background: In the SOLOIST-WHF (Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure) trial, sotagliflozin, a sodium-glucose cotransporter-1 and sodium-glucose cotransporter-2 inhibitor, reduced total occurrences of cardiovascular deaths, hospitalizations for heart failure, and urgent visits for heart failure relative to placebo by 33%. Objective: To determine whether sotagliflozin increased the prespecified efficacy outcome of days alive... 
VO  -  
IS  -  
SP  -  
OP  -  
KW  - INHIBITORS; COVID-19; EVENTS; 3121 General medicine, internal medicine and other clinical medicine 
N1  -   
PP  -  
ER  -